Status:
COMPLETED
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Lead Sponsor:
Alcon Research
Conditions:
Angle-closure Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chroni...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Chronic Angle Closure Glaucoma (CACG)
- 21-35 millimeters mercury mean intraocular pressure on Eligibility visit day at 9 AM
- Peripheral iridotomy performed ≥ 1 Month prior to the Screening visit
- Anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation
- Peripheral anterior synechiae (PAS)
Exclusion
- Traumatic damage of the anterior chamber angle
- History of ocular inflammation or surgery (except for iridotomy) ≤ 3 months
- Patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks
- Visual Acuity ≥ 1.0
- Contact lenses wearer
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00762645
Start Date
February 1 2007
End Date
May 1 2008
Last Update
December 6 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.